Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high5.2450 15/03/16
52 week low2.2650 21/01/16
52 week change 0.8000 (33.68%)
4 week volume34,005,486 26/12/16

Media for (VRP)

Presenter: Jan-Anders Karlsson
27/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Publication of Circular

RNS Number: 4091U Verona Pharma PLC 18 January 2017 18 January 2017 FOR RNS RELEASE: THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN O...

Holding(s) in Company

RNS Number: 8462T Verona Pharma PLC 11 January 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Verona Pharma Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acq...

Holding(s) in Company

Notification of major interests in shares

Issue of Equity

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

Verona Pharma plans US public offering

Verona Pharma announces that it plans to conduct a registered initial public offering in the US. The number of shares an...

Registered Initial Public Offering in the US

Miscellaneous medium priority announcements

Exercise of options

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

Second Venture and Innovation Award from the CF Trust

Statement regarding a particular issue

Fundamental DataMore

EPS-0.73
Dividend yield0 %

Equity Research (VRP)

edison investment research
Verona Pharma plc
26/07/2016
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development...
hardman & co
Verona Pharma plc
20/06/2016
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which...
hardman & co
Verona Pharma plc
16/03/2016
VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced...

Latest discussion posts More

  • Re: Tired and Confused

    I'm not hoping for a buy out. I'm in for a caca or bust finale with either a multibagger return or burger all. If I wanted a less volatile investment I would have bought ...
    20-Jan-2017
    Tired and Confused
  • Re: Less vitriol please

    My father died from cold. Enough said. I fully support the business and hope they succeed. That would be a win win, yes?
    20-Jan-2017
    Tired and Confused
  • Re: Tired and Confused

    If the drug show any chance to be successful, it is likely this company would be bought out and likely candidate comes to my mind is 'Vectura'.
    20-Jan-2017
    raptor66

Users' HoldingsMore

Users who hold Verona Pharma also hold..
LLOYDS GRP.21%
GULF KEYSTONE12%
RENEURON10%
RANGE RES.10%
SIRIUS MINERALS9%

Codes & Symbols

ISINGB00B06GSH43
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP